- Home
- LUCY vs APM Comparison
LUCY vs APM Comparison
Compare LUCY & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | APM |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United Kingdom |
| Employees | 13 | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 5.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | LUCY | APM |
|---|---|---|
| Price | $0.65 | $0.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.5M | 57.4K |
| Earning Date | 05-14-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $175.92 | N/A |
| Revenue Next Year | $205.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.60 |
| 52 Week High | $2.27 | $4.47 |
Technical Indicators
Market Signals| Indicator | LUCY | APM |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 34.93 |
| Support Level | $0.66 | $0.65 |
| Resistance Level | $1.15 | $0.89 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 1.77 | 42.86 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.
About APM Aptorum Group Limited
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.